NEIL2: A Potential Drug Target and Biomarker for Endonuclease 8-Like 2

Target Name: NEIL2

NCBI ID: G252969

NEIL2

NEIL2: A Potential Drug Target and Biomarker for Endonuclease 8-Like 2

Endonuclease 8-like 2 (ENL-2) is a enzyme that plays a crucial role in the regulation of DNA double-strand break repair. Mutations in the ENL-2 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting ENL-2 with drugs has the potential to treat a range of diseases. One potential drug target for ENL-2 is the Neuronal Extravascular Enzyme-2 (NEIL2) gene, which encodes a protein involved in the treatment of neurodegenerative diseases.

NEIL2: A Potential Drug Target

The neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of nerve cells and the development of neurotransmitter deficits. These diseases are often treated with drugs that aim to slow down or halt the progression of neurodegeneration. However, these drugs often have limited efficacy and may cause unintended side effects. Therefore, there is a need for new drug targets that can provide more targeted and effective treatments.

The NEIL2 gene was identified as a potential drug target for ENL-2 because it encodes a protein that is involved in the repair of DNA double-strand breaks. This protein has been shown to interact with ENL-2 and may play a role in regulating ENL-2 activity. Therefore, targeting the NEIL2 gene with drugs that inhibit ENL-2 activity could potentially lead to new treatments for neurodegenerative diseases.

NEIL2: A Potential Biomarker

In addition to its potential as a drug target, NEIL2 has also been identified as a potential biomarker for neurodegenerative diseases. The neurodegenerative diseases are characterized by the progressive loss of nerve cells and the development of neurotransmitter deficits. Therefore, the level of NEIL2 protein in brain tissue can be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases.

One approach to use NEIL2 as a biomarker is to measure the level of NEIL2 protein in brain tissue from patients with neurodegenerative diseases. The levels of NEIL2 protein can be used to assess the severity of disease, monitor disease progression, and evaluate the effectiveness of new treatments. For example, if a patient with Alzheimer's disease has a lower level of NEIL2 protein in their brain tissue, a drug that targets ENL-2 activity and reduces the level of NEIL2 protein could potentially lead to improved disease symptoms.

Conclusion

In conclusion, NEIL2 is a potential drug target and biomarker for ENL-2, which is involved in the regulation of DNA double-strand break repair. The identification of NEIL2 as a potential drug target and biomarker for ENL-2 has the potential to revolutionize the treatment of neurodegenerative diseases. Further research is needed to understand the full potential of NEIL2 as a drug target and biomarker for ENL-2.

Protein Name: Nei Like DNA Glycosylase 2

Functions: Involved in base excision repair of DNA damaged by oxidation or by mutagenic agents. Has DNA glycosylase activity towards 5-hydroxyuracil and other oxidized derivatives of cytosine with a preference for mismatched double-stranded DNA (DNA bubbles). Has low or no DNA glycosylase activity towards thymine glycol, 2-hydroxyadenine, hypoxanthine and 8-oxoguanine. Has AP (apurinic/apyrimidinic) lyase activity and introduces nicks in the DNA strand. Cleaves the DNA backbone by beta-delta elimination to generate a single-strand break at the site of the removed base with both 3'- and 5'-phosphates

The "NEIL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEIL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets